- The Wall Street Journal•4 hours ago
President Donald Trump’s pick to lead the Food and Drug Administration plans to recuse himself for a year from agency decisions on more than 20 companies—including several drug giants.
- Reuters•14 hours ago
The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies. Sanofi and Regeneron said the drug, Dupixent, will have a list price of $37,000 a year. Sanofi said is has been encouraged by conversations with health plans and pharmacy benefit managers about patient coverage for Dupixent.
- Market Realist•17 hours ago
GSK's Consumer Health revenues increased ~9% during 2016 to ~7.2 billion pounds. The increase was mainly due to the Wellness and Skin Health franchise.
GSK.L : Summary for GLAXOSMITHKLINE PLC ORD 25P - Yahoo Finance
GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||1,682.00 x 175400|
|Ask||1,682.50 x 417900|
|Day's Range||1,681.00 - 1,689.50|
|52 Week Range||1,363.00 - 1,745.56|
|PE Ratio (TTM)||90.46|
|Dividend & Yield||1.01 (4.89%)|
|1y Target Est||N/A|